7 min read

Daily Filing Digest — Monday, 28 Sep 2026

28 Sep 2026: Anupam Rasayan takes control of Bliss GVS, ITC takes Yoga Bar to 100%, KPIL wins a ₹4,000 crore-plus UAE pipeline order.

A heavy Monday. Anupam Rasayan completed its takeover of Bliss GVS Pharma, financed mostly by Bain Capital-led investors, and its filings give Purebliss Pharma Solutions, the company receiving the equity-like funding, a ₹1 option over the Bliss stake if the financing defaults. ITC bought out the rest of Yoga Bar for about ₹645 crore. Kalpataru Projects won a UAE gas pipeline worth over ₹4,000 crore, and Dilip Buildcon, NCC and Ellenbarrie added about ₹3,400 crore of orders between them. Ola Electric and Natco Pharma moved ahead with rights issues. Two chief executives, at Trident and Allcargo, announced they are leaving their posts.

The one to read first

Bliss GVS Pharma has a new controlling shareholder. Anupam Rasayan said it has paid for a 48.2% controlling stake at ₹299 a share, through its wholly owned subsidiary Mates Visa Consultancy.

  • Funding: a ₹300 crore term loan plus about ₹1,450 crore "raised through non-controlling, non-voting instruments from a group of financial investors led by Bain Capital and including Trust Group and Investec".
  • Anupam says the price was about 24 times Bliss GVS's trailing earnings.
  • Bliss GVS's board recorded Anupam Rasayan and Mates as promoters, holding 5,09,86,264 shares (47.95%). Managing Director Narsimha Kamath resigned and three new non-independent directors joined.
  • The outgoing promoters, who together held 34.82%, move to the public category.

The detail that matters is in Anupam's 23 September filings. The subsidiary holding the Bliss stake has granted an option to buy all of it, for ₹1, to Purebliss Pharma Solutions, in which Anupam holds 15%. The option can be used only after certain defaults on the subsidiary's financing.

Full read: Anupam Rasayan Buys Bliss GVS, With a ₹1 Option Attached

Deals

Orders

Capital

Courts, regulators and tax

Management

  • Trident: Group CEO Samir Joshipura resigned for personal reasons, effective 30 September.
  • Allcargo Logistics: MD & CEO Ketan Kulkarni moves to a group Chief Growth Officer role from 1 January 2027. Vijay Nehra becomes MD Designate from 1 October and MD & CEO for five years from 1 January, subject to shareholders' approval.
  • Coforge appointed Akhil Kumar Gupta, a former Vice Chairman of Bharti Enterprises, as an independent director and Chairperson for five years.
  • Repro India's CFO Abhinav Vohra resigned, effective 31 December.

Operations

Shareholdings and pledges

The fine print

Dates to note

  • 28–30 Sep bank strike: deferred. Central Bank of India says the unions deferred both the 28–30 September strike and the continuous strike planned from 26 October, after talks with the IBA.
  • 29 Sep: Som Distilleries AGM.
  • 1 Oct: record date for Natco Pharma's rights issue; the issue opens 12 October. Most trading windows close ahead of September-quarter results.
  • 5–16 Oct: SMC Global Securities' public NCD issue of up to ₹150 crore.
  • 9 Oct: record date for 1:1 bonuses at Mold-Tek Technologies and Mold-Tek Packaging.
  • By 9 Oct: the court's deadline for renewing Som Distilleries' licences.
  • 2 Nov: Maruti Suzuki's CCI hearing resumes.

What we're not reporting

This digest covers NSE filings only. From 28 September, our filing feed reads NSE alone while BSE's access block continues, so BSE-only filings are not in it.

Six NSE documents could not be downloaded. One filing, Sedemac Mechatronics' stake sale disclosure, dates the sale to 2024, which cannot be right; it is held back until corrected.

The rest of the day was mostly trading-window closures, AGM results, ESOP allotments and record dates.


Educational research, not investment advice. Every figure above is drawn from the named company's own filing dated 28 September 2026 (or the date stated) and checked against the source; where a filing disclosed no value, none is stated. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.